Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma

Healthy lifestyle may offset risk of lethal prostate cancer in men with high genetic risk

SMMART Program: A multi-omics tumour board with a focus on breast cancer

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma

Clinical validation of a targeted methylation-based multi-cancer early detection test

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer